首页 | 本学科首页   官方微博 | 高级检索  
     


Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial
Affiliation:1. Clinical Trials Research Unit, University of Leeds, Leeds, UK;2. St James''s Institute of Oncology, St James University Hospital, Leeds, UK;3. Nuffield Department of Population Health, Oxford University, Oxford, UK;4. Department of Clinical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, UK;5. Department of Medical Oncology, University Hospitals, Bristol, UK;6. Department of Medical Oncology, Velindre Hospital, Cardiff, UK;7. Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK;1. Ministry of Health, Chilaw, Sri Lanka;2. Sri Lanka Cancer Research Group, Maharagama, Sri Lanka;3. Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;4. The Christie NHS Foundation Trust, Manchester, UK;1. NHS England & Royal College of Radiologists, London, UK;2. Royal College of Radiologists, London, UK;1. School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK;2. Radiotherapy Research Group, Leeds Institute of Medical Research at St James''s, Faculty of Medicine & Health, University of Leeds, Leeds, UK;3. Leeds Cancer Centre, The Leeds Teaching Hospitals NHS Trust, Leeds, UK;4. Department of Medical Physics & Biomedical Engineering, University College London, London, UK;5. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK;7. Velindre Cancer Centre, Cardiff, UK;1. Institute of Cancer Sciences, University of Glasgow, Glasgow, UK;2. Beatson West of Scotland Cancer Centre, Glasgow, UK;3. Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK;4. University of Leeds and Leeds Cancer Centre, Faculty of Medicine & Health, University of Leeds, UK;5. Oxford University NHS Foundation Trust, Oxford, UK;1. Department of Clinical Oncology, Mount Vernon Cancer Centre, Northwood, UK;2. Department of Radiotherapy Physics, Mount Vernon Cancer Centre, Northwood, UK;3. Department of Acute Medicine, University Hospital Lewisham, London, UK;4. Department of Clinical Oncology, St Bartholomew''s Hospital, London, UK;5. Division of Cancer Sciences, The University of Manchester, Manchester, UK;1. Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada;2. Department of Radiation Oncology, BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada;3. Department of Radiation Oncology, BC Cancer Agency Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, Canada;4. Department of Radiation Oncology, BC Cancer Agency Abbostford Centre, Abbotsford, British Columbia, Canada;5. Department of Radiation Oncology, BC Cancer Agency Fraser Valley Centre, Surrey, British Columbia, Canada;7. Department of Radiation Oncology, BC Cancer Agency Vancouver Island Centre, Vancouver Island, British Columbia, Canada;11. Department of Population Oncology, British Columbia Cancer Vancouver Centre, Vancouver, British Columbia, Canada
Abstract:
Keywords:Brain metastases  breast cancer  HER2  lapatinib  radiotherapy  trastuzumab
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号